Targeting Oxidative Stress in Neurodegenerative Diseases: Report

This report provides researchers and medical-affairs teams with actionable insights into antioxidant-based therapeutic strategies for neurodegenerative diseases. Three illustrative findings are highlighted below, drawn from a comprehensive 494-page analysis; additional insights are provided in the full report.

• TG15‑132, a selective Nox2 inhibitor, reduces ROS and inflammatory gene expression while penetrating the brain effectively—making it a strong candidate for oxidative stress–linked neurodegeneration.
• ApoE4 expression impairs neuronal mitochondria, reducing ATP and elevating ROS, suggesting the need for mitochondrial‑targeted interventions to counteract ApoE4‑related cognitive decline.
• Antioxidant therapy in MS patients cut ROS by 15% and reduced lipid peroxidation and DNA oxidation by 41% and 32%, respectively—supporting clinical use to manage oxidative injury and inflammation.

• Records screened: 6603
• Full-text studies included: 784
• Coverage window: Jan 2018–Mar 2025